Open Access Open Badges Meeting report

A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies

Adrian Bot1*, Mark Ahn2, Marnix Bosch3, Dirk Brockstedt4, Lisa H Butterfield5, Andrew Cornforth6, Richard Harrop7, W Martin Kast8, Richard Koya9, Francesco Marincola10, Kim Margolin11, Candice McCoy12, Graham Pawelec13, John Rothman14, Teresa Ramirez-Montagut14, Jeffrey Schlom15, Pramod Srivastava16, Sarah Wallis17, Steffen Walter18, Ena Wang10 and John Waslif19

Author Affiliations

1 Kite Pharma Inc, Los Angeles, CA, USA

2 Galena Biopharma, Inc, Lake Oswego, OR, USA

3 Northwest Biotherapeutics, Bethesda, MD, USA

4 Aduro Biotech, Berkeley, CA, USA

5 Department of Medicine, Surgery and Immunology, UPCI Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, Pittsburgh, PA, USA

6 California Stem Cell, Irvine, CA, USA

7 Oxford BioMedica, Oxford, UK

8 Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA

9 Department of Surgical Oncology, University of California Los Angeles, Los Angeles, CA, USA

10 Department of Transfusion Medicine; Infectious Disease and Immunogenetics Section, National Institutes of Health, Bethesda, MD, USA

11 Division of Medical Oncology, University of Washington, Seattle, WA, USA

12 Dendreon Corp, Seattle, WA, USA

13 Center for Medical Research, University of Tübingen, Tübingen, Germany

14 Advaxis Inc Genomics Institute of the Novartis Research Foundation, Princeton, NJ, USA

15 Immunotherapeutics Group, National Institutes of Health, Bethesda, MD, USA

16 Department of Immunology, University of Connecticut Health Center, Farmington, CT, USA

17 Arrowhead Publishers and Conferences, Minneapolis, MN, USA

18 Immatics Biotechnologies GmbH, Tübingen, Germany

19 Arrowhead Publishers and Conferences, Minneapolis, MN, USA

For all author emails, please log on.

Journal of Translational Medicine 2012, 10:218  doi:10.1186/1479-5876-10-218

Published: 5 November 2012


While there has been significant progress in advancing novel immune therapies to the bedside, much more needs to be done to fully tap into the potential of the immune system. It has become increasingly clear that besides practical and operational challenges, the heterogeneity of cancer and the limited efficacy profile of current immunotherapy platforms are the two main hurdles. Nevertheless, the promising clinical data of several approaches point to a roadmap that carries the promise to significantly advance cancer immunotherapy. A new annual series sponsored by Arrowhead Publishers and Conferences aims at bringing together scientific and business leadership from academia and industry, to identify, share and discuss most current priorities in research and translation of novel immune interventions. This Editorial provides highlights of the first event held earlier this year and outlines the focus of the second meeting to be held in 2013 that will be dedicated to stem cells and immunotherapy.